Table 2.

Changes in lipid levels according to EULAR response at 1 and 4 months of therapy.

	Baseline	1 Month	4 Months
EULAR nonresponders
Total cholesterol, mmol/l	5.03 ± 0.96	5.09 ± 1.10	4.98 ± 1.03
Triglycerides, mmol/l	1.32 ± 0.54	1.29 ± 0.53	1.23 ± 0.49
HDL cholesterol, mmol/l	1.29 ± 0.50	1.30 ± 0.51	1.30 ± 0.46
LDL cholesterol, mmol/l	3.40 ± 0.76	3.42 ± 0.82	3.34 ± 0.78
Total cholesterol/HDL ratio	4.39 ± 1.76	4.41 ± 1.69	4.23 ± 1.65
ApoA-I, mg/dl	1.79 ± 0.39	1.78 ± 0.32	1.79 ± 0.31
ApoA-II, mg/dl	0.31 ± 0.08	0.32 ± 0.09	0.31 ± 0.08
ApoB, mg/dl	1.25 ± 0.29	1.26 ± 0.33	1.21 ± 0.28
ApoE, mg/dl	0.04 ± 0.02	0.04 ± 0.02	0.04 ± 0.01
ApoC-III, mg/dl	0.11 + 0.04	0.11 ± 0.04	0.10 ± 0.03
ApoB/ApoA-I ratio	0.75 ± 0.34	0.73 ± 0.21	0.74 ± 0.31
EULAR good responders
Total cholesterol, mmol/l	4.88 ± 0.96	4.78 ± 0.88	4.95 ± 1.02
Triglycerides, mmol/l	1.19 ± 0.53	1.18 ± 0.60	1.26 ± 0.60
HDL cholesterol, mmol/l	1.24 ± 0.40	1.27 ± 0.44^*	1.30 ± 0.39^*
LDL cholesterol, mmol/l	3.30 ± 0.83	3.16 ± 0.75	3.26 ± 0.85
Total cholesterol/HDL ratio	4.38 ± 1.98	4.16 ± 1.53^*	4.16 ± 1.66^*
ApoA-I, g/l	1.78 ± 0.33	1.75 ± 0.25	1.78 ± 0.33
ApoA-II, g/l	0.29 ± 0.06	0.31 ± 0.06^*	0.31 ± 0.06^*
ApoB, g/l	1.20 ± 0.33	1.14 ± 0.30^*	1.18 ± 0.31^*
ApoE, g/l	0.05 ± 0.03	0.04 ± 0.03	0.05 ± 0.02
ApoC-III, g/l	0.09 ± 0.03	0.09 ± 0.03	0.10 ± 0.03
ApoB/ApoA-I ratio	0.70 ± 0.26	0.67 ± 0.21^*	0.67 ± 0.23^*

↵* Generalized estimating equation analyses were used to test for longitudinal changes in lipids. There were significant differences at 1 and 4 months of therapy compared to baseline for HDL (p = 0.006), TC/HDL ratio (p = 0.014), ApoA-II (p = 0.004), ApoB (p = 0.013), and ApoB/ApoA-I ratio (p = 0.001). EULAR: European League Against Rheumatism; HDL: high-density lipoprotein; LDL: low-density lipoprotein; apo: apolipoproteins.